Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment reporting

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05557604Phase 2Recruiting

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

Role: lead

SYF817a6504962249f597c8ccdccecdb5d5Phase 2Unknown

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo

Role: lead

SYFc36139409ea1458b8bec8c062f5718f7Phase 2Not Yet Recruiting

VINORELBINE INHIBITS ONCOGENIC FUNCTIONS OF MKK3: A NEW THERAPEUTIC OPPORTUNITY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

Role: lead

SYFdfa9c10820fd417e91c34caccaa0ac91Phase 2Not Yet Recruiting

“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”

Role: lead

SYFec6873a4f3594ae4ac1798649bce6e9aPhase 2Unknown

PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study

Role: lead

All 5 trials loaded